Figure 3.
Venn diagram of the risk model using two risk factors, including the number of metastatic sites (1/≥2) and the neutrophil–lymphocyte ratio (≤3.50/>3.50) at the initiation of pembrolizumab treatment in 212 mUC patients.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.